Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Patients with biochemically recurrent prostate cancer and short prostate‐specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itraconazole as a potentially noncastrating treatment approach in biochemically recurrent prostate cancer. Patients and Methods Patients with biochemically recurrent prostate cancer and PSADT ≤ 15 months, with serum testosterone > 150 ng/dL, were prospectively enrolled. The primary end point was the proportion of patients who experienced ≥ 50% decline from baseline in serum prostate‐specific antigen (PSA) by week 12. Results Twenty‐one patients were enrolled. The median (range) age, baseline PSA, and PSADT at study entry was 72 (49‐76) years, 7.6 (1.5‐45.5) ng/mL, and 5.7 (1.2‐13.0) months, respectively. Among 19 patients with evaluable data, 1 patient (5%) had a > 50% PSA decline. Nine patients (47%) experienced any PSA decline (mean decline 25.0%, range 2%‐60%) by week 12. Among 10 patients without a PSA decline, the on‐treatment versus pretreatment PSADT was not significantly longer (median 6.8 vs. 4.3 months, P = .17). There was no significant change from baseline to week 12 in serum testosterone (median change = 32.4%, P = .21) or androstenedione (median change = −8.3%, P = .85). The most common adverse events were edema (52%), fatigue (38%), hypertension (24%), and hypokalemia (24%). Conclusion Itraconazole modulates serum PSA levels without lowering serum testosterone. However, the magnitude of effect is modest, and treatment carries risk of toxicities associated with mineralocorticoid excess. Micro‐Abstract Itraconazole has been previously shown to have antitumor activity independent of its effect on circulating androgen levels and was therefore investigated as a noncastration approach in patients with biochemically recurrent prostate cancer. Results indicate that itraconazole indeed has a modest impact on serum prostate‐specific antigen levels without affecting circulating androgen levels. However, toxicities pertaining to mineralocorticoid excess limits the further development of itraconazole in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.027 · Cited by 527
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Antonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D., Blackford, A. L., Danila, D. C., King, S., Frost, A., Ajiboye, A. S., Zhao, M., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-314 · Cited by 180
Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer
Aftab, B. T., Dobromilskaya, I., Liu, J. O., & Rudin, C. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0691 · Cited by 167
Cited by
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Lima, T. S., Souza, L. O., Iglesias-Gato, D., Elversang, J., Jørgensen, F. S., Kallunki, T., Røder, M. A., Brasso, K., & Moreira, J. M. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869461 · Cited by 26
“Unlike other azole antifungal drugs, ITZ does not block gonadal and adrenal steroidogenesis, suggesting it may potentially have value as a non-castrating treatment approach, but clinical studies of ITZ in biochemically recurrent prostate cancer, showed that ITZ had only a modest effect (Lee et al., 2019).”
BackgroundQuality by design empowered preparation of itraconazole albumin nanoparticles for prostate cancer
Shah, S., Famta, P., Sharma, A., Kumar, R., Pandey, G., Vambhurkar, G., Srinivasarao, D. A., Shinde, A., Prasad, S. B., Asthana, A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01592-z · Cited by 12
“Such a repurposed drug, itraconazole (ITR), which is widely used as an anti-fungal agent, showed tremendous potential in the treatment of biochemically recurrent PCa [4], by causing apoptosis, autophagy, cell cycle arrest and/or growth inhibition of tumor cells [5].”
Kast, R. E. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030153 · Cited by 5
Kast, R. E. (2024) · Cells · doi:10.3390/cells13141175 · Cited by 4
“Important to note here is that 200 mg itraconazole was without effect [74,75].”
Background
Metadata
- Authors
- Lee, M., Hong, H., Kim, W., Zhang, L., Friedlander, T. W., Fong, L., Lin, A. M., Small, E. J., Wei, X. X., Rodvelt, T. J., Miralda, B., Stocksdale, B., Ryan, C. J., & Aggarwal, R.
- Venue
- Clinical Genitourinary Cancer
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 17
- Issue
- 1
- Pages
- e92-e96
- ISSN
- 1558-7673 (ISSN-L)
- OpenAlex
- W2894040066
- Cited by
- 28
- References
- 6
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.